黑色素瘤是一种极易发生转移的恶性皮肤肿瘤,具有高度的致死性。上皮-间充质细胞转化(Epithelial-mesenchymal transition, EMT)在胚胎发育过程中起到非常重要的作用,同时在肿瘤的发生和恶化过程中也扮演着重要的角色。miRNA具有广谱的调节能力,对于肿瘤发生和EMT形成都能产生不同程度的影响。本文整合黑色素瘤细胞系转录组和miRNA组测序数据,在转录组数据中筛选得到参与肿瘤EMT过程的基因,通过Mirsystem软件预测并从miRNA组数据中筛选出与之负相关的11个miRNA,包括miR-130a-3p、miR-130b-3p、miR-125a-5p、miR-30a-3p、miR-195-5p、miR-345-5p、miR-509-3-5p、miR-374a-5p、miR-509-5p、miR-148a-3p和miR-330-3p。经过生物信息学分析miRNA靶基因富集的分子网络和信号途径,发现了两个与细胞发育和细胞间相互作用密切相关的网络,以及多个参与调控EMT过程的信号通路。对11个miRNA进行分子生物学验证,发现miR-195-5p、miR-130a-3p、miR-509-5p和miR-509-3-5p共4个可以调节重要肿瘤基因的miRNA。本研究运用mRNA和miRNA两种转录组的测序数据筛选EMT相关miRNA的方法,为肿瘤多组学数据整合分析提供了新的研究思路,并以期能为肿瘤精准基因组学的发展发挥重要的推进作用。
Melanoma is a malignant cutaneous cancer of high metastasis and lethal rates. Epithelial-mesenchymal transition (EMT) plays an important role in the embryonic developmental process that is often activated during tumorigenesis and metastasis. In this study, we integrated of mRNA and miRNA transcriptome sequencing data of melanocyte and melanoma cell lines to identify genes involved in the process of tumor EMT in the first place, and uncovered 11 miRNAs including miR-130a-3p, miR-130b-3p, miR-125a-5p, miR-30a-3p, miR-195-5p, miR-345-5p, miR-509-3-5p, miR-374a-5p, miR-509-5p, miR-148a-3p and miR-330-3p, negatively related with EMT genes using the Mirsystem software. Bioinformatics analysis with target genes of these miRNAs revealed two networks closely related with cellular development and cell-to-cell interactions, as well as multiple signaling pathways participating in EMT. Validation of the 11 miRNAs with molecular biology experiments demonstrated that four miRNAs regulated oncogenes in melanomas, including miR-195-5p, miR-130a-3p, miR-509-5p, and miR-509-3-5p. Our study integrates two kinds of omics data to screen for EMT-related miRNAs, providing a new research idea in the precision genomics of cancer research.
[1] Pacheco I, Buzea C, Tron V. Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med , 2011, 13: e33.
[2] Lujambio A, Lowe SW. The microcosmos of cancer. Nature , 2012, 482(7385): 347-355.
[3] Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin , 2010, 60(5): 301-316.
[4] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol , 2014, 15(3): 178-196.
[5] Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial- mesenchymal transitions in development and disease. Cell , 2009, 139(5): 871-890.
[6] Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell , 2008, 14(6): 818-829.
[7] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 . Cell , 1993, 75(5): 843-854.
[8] Mione M, Bosserhoff A. MicroRNAs in melanocyte and melanoma biology. Pigment Cell Melanoma Res , 2015, 28(3): 340-354.
[9] Dar AA, Majid S, Rittsteuer C, De Semir D, Bezrookove V, Tong S, Nosrati M, Sagebiel R, Miller JR, III, Kashani- Sabet M. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst , 2013, 105(6): 433-442.
[10] Poenitzsch Strong AM, Setaluri V, Spiegelman VS. MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. Arch Biochem Biophys , 2014, 563: 118-124.
[11] Aigner A. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis- related miRNAs. J Mol Med , 2011, 89(5): 445-457.
[12] Sims D, Sudbery I, Ilott NE, Heger A, Ponting CP. Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet , 2014, 15(2): 121-132.
[13] Schneeberger K. Using next-generation sequencing to isolate mutant genes from forward genetic screens . Nat Rev Genet , 2014, 15(10): 662-676.
[14] Sarda S, Hannenhalli S. Next-generation sequencing and epigenomics research: a hammer in search of nails. Genomics Inform , 2014, 12(1): 2-11.
[15] Danielsson K, Mun LJ, Lordemann A, Mao J, Lin CHJ. Next-generation sequencing applied to rare diseases genomics. Expert Rev Mol Diagn , 2014, 14(4): 469-487.
[16] Zhao H, Li YJ, Wang SB, Yang YD, Wang JY, Ruan XY, Yang YR, Cai K, Zhang B, Cui P, Yan JW, Zhao YL, Wakeland EK, Li QZ, Hu SN, Fang XD. Whole transcriptome RNA-seq analysis: tumorigenesis and metastasis of melanoma. Gene , 2014, 548(2): 234-243.
[17] The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature , 2014, 511(7511): 543-550.
[18] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature , 2014, 513(7517): 202-209.
[19] Ouyang M, Li YX, Ye S, Ma JY, Lu LM, Lv WM, Chang GQ, Li XX, Li Q, Wang SM, Wang WJ. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One , 2014, 9(5): e96228.
[20] Mitra R, Edmonds MD, Sun JC, Zhao M, Yu H, Eischen CM, Zhao ZM. Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non- small cell lung cancer. RNA , 2014, 20(9): 1356-1368.
[21] Ben-Hamo R, Efroni S. MicroRNA-gene association as a prognostic biomarker in cancer exposes disease mechanisms. PLoS Comput Biol , 2013, 9(11): e1003351.
[22] Elgaaen BV, Olstad OK, Haug KBF, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer , 2014, 14: 80.
[23] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell , 2000, 100(1): 57-70.
[24] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell , 2011, 144(5): 646-674.
[25] Sekulic A, Haluska P, Jr., Mille
